Deal volume in 2026 is substantially outpacing last year, and activity is being driven by interest in cancer and autoimmune ...
It’s easy to assume that more data = better models = faster identification. With AI, you can extract associations between ...
Even though Elevidys beat Wall Street expectations, analysts expect investor focus to shift toward Sarepta's early-stage RNA ...
The acquisition hands the Italian pharma a group of medicines approved to treat various CNS disorders and gives it wider ...
PathAI makes AI models that help with the analysis of patient tissue samples and diagnostic tools. Roche has partnered with ...
After withdrawing its initial filing last year, the immune drugmaker rebounded and added to a recent run of sizable new ...
A Series D round led by Venrock will support an ongoing Phase 2 study, and planned Phase 3 trial, of an oral drug the biotech ...
Avalo reported study success in what’s proven to be a tough-to-treat skin disease. Elsewhere, BioNTech announced plans to close multiple plants and Madrigal picked up an RNA-based drug for MASH.
Whereas earlier Phase 3 results disappointed Wall Street, new findings in people with “chronic” disease were viewed by ...
Settlements delaying the arrival of generic versions of tafamidis will protect billions in Pfizer revenue and have ...
Seaport Therapeutics and Hemab Therapeutics on Thursday became the latest drugmakers to debut on Wall Street, continuing a ...
The British biotechnology startup is making "pan-gamma delta” T cell engagers it says can address the limitations of similar, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results